Peptides are having a moment: what the ads don't tell you

Peptides are having a moment. On August 30, 2026, the Minnesota Star Tribune ran a widely shared analysis titled “Peptides are having a moment. Here’s what the ads don’t tell you,” describing how the word “peptide” has “moved from biochemistry textbooks into podcasts, gym locker rooms and Instagram ads.”[1] It crystallizes what regulators and safety researchers have been saying for a year: the marketing of unapproved peptides has outrun the evidence.[1]

This guide is our science-first response: the GLP-1 halo effect, FDA Category 2, the evidence on BPC-157 and TB-500, the July 2026 advisory vote, and a checklist for evaluating any peptide claim.

Update (Sept 3, 2026): The evidence side of this story landed days later — UCLA Health’s September 2026 review of six popular peptide supplements (BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu) found little evidence and concluded all six “cannot be recommended.” Read the per-peptide evidence breakdown: UCLA Health reviewed 6 peptides: the evidence.

Why the GLP-1 halo is making every peptide look legitimate

The core of the problem is what the Star Tribune calls a “halo effect.”[1] The success of Ozempic and Wegovy — FDA-approved GLP-1 drugs that have helped millions — has made the category “peptide” feel trustworthy by association.[1] Insulin is a peptide. Semaglutide is a peptide. Both went through years of clinical testing, and for their approved uses the FDA judged that benefits outweigh risks.[1]

But BPC-157, TB-500, KPV, GHK-Cu, MOTS-c and ipamorelin are also peptides — and none of them is FDA-approved.[1] As the Star Tribune put it: “Many people now assume that if some peptides are effective medicines, other peptides marketed for recovery, anti-aging and performance enhancement must be similarly vetted. They are not.”[1]

The scale is large and growing: the global peptide market has “swelled to more than $50 billion in annual sales,” projected to nearly double again in the next decade.[16]

FDA Category 2, explained

What “may present significant safety risks” means

Category 2 is part of FDA’s framework for bulk drug substances used in compounding under sections 503A and 503B of the FD&C Act.[2] In FDA’s own words, “Bulk drug substances that may present significant safety risks have been placed in category 2 under the interim policies.”[2] It is a screening flag — not a ban, an approval, or an authorization to compound.[2]

In September 2023, the FDA placed 19 peptides on the Category 2 list, including BPC-157 and TB-500.[19] The agency’s stated concerns went beyond impurities: potential for peptides to clump together, risk of immune reactions, difficulty confirming what is actually in a batch, and a thin-to-absent record of human safety.[1]

Why removal from the list isn’t approval

On April 15, 2026, the FDA formally removed 12 peptides from Category 2 — including BPC-157, TB-500 (thymosin beta-4 fragment), MOTS-c, KPV, Epitalon, Semax and GHK-Cu.[19] That sounds like good news, but it was procedural: the removals happened because nominations were withdrawn, not because the safety concerns resolved.[2]

The result is a regulatory gray zone. BPC-157 and TB-500 are “not banned, not approved, not on the list of substances pharmacies may compound, and still carrying the FDA’s published safety concerns.”[1]

BPC-157 and TB-500: what the marketing claims vs. what the evidence shows

BPC-157 is one of the most popular peptides in this group.[1] It is marketed for faster recovery from injury and reduced inflammation; TB-500 is marketed as having similar benefits.[1] The Star Tribune’s summary is blunt: “the marketing for these substances is much stronger than the science.”[1]

The FDA’s own records back that up.[2] Its Category 2 entry for BPC-157 warns that compounded products “may pose risk for immunogenicity for certain routes of administration” and may have “complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization,” adding that the FDA has “identified no, or only limited, safety-related information for the proposed routes of administration.”[2]

For TB-500 the gap is even starker: “FDA has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment.”[2] There is no established human safety record at all.[2]

The July 2026 advisory briefing reached the same conclusion.[5] FDA scientists found “insufficient clinical safety information to characterize the safety profile of BPC-157” and “no studies that administered BPC-157 to humans via the proposed oral, SC, nasal, or transdermal ROA” — the routes people actually use.[5]

What the July 2026 FDA advisory vote actually did (and didn’t)

On July 23-24, 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) considered seven peptides: BPC-157, KPV, TB-500, MOTS-c, emideltide, Epitalon and Semax.[6] It voted 8-6 with one abstention to recommend that BPC-157 (for ulcerative colitis) and KPV (for wound treatment and inflammatory conditions) be added to the 503A Bulks List.[7]

Three facts matter more than the headline vote:

FDA staff recommended against all seven. “The FDA’s own scientists recommended against changing the status of any of the seven peptides under consideration,” citing insufficient evidence to establish safety or effectiveness.[10]

The reviewed uses are not the marketed uses. “BPC-157 was reviewed for ulcerative colitis. TB-500 and KPV for wound healing. MOTS-c for obesity and osteoporosis. Epitalon for insomnia.” Not tendon repair, gym recovery or longevity.[1]

A recommendation is not approval. “The FDA does not have to follow it. Any change still has to clear a proposed rule, a public comment period and a final rule, which would likely take a year at minimum. Nothing you can legally buy changed last month.”[1]

The gap between what the committee reviewed and what the market sells is itself a warning sign: the ads and the docket are describing different drug uses.[1]

Red flags in peptide ads and influencer content

“Research use only” is legal positioning, not a safety warning. These disclaimers “act as legal positioning” — they let a seller avoid marketing a product as a drug, and say nothing about purity, sterility or safety.[15]

Influencer discount codes are paid promotion. “Influencers frequently provide personalized discount codes, offering followers between 5% and 30% off purchases. Each click redirects buyers to online peptide vendors, generating commission for the influencer.”[15]

Missing FDA-status disclaimers. The Star Tribune’s audit of wellness clinics in the Twin Cities found that, of the handful openly advertising peptide therapies, only one posted a clear disclaimer about FDA status.[1]

The enforcement record is real. The FDA has issued warning letters to companies selling unapproved peptides through the gray market,[13] and adverse-event reports tied to compounded GLP-1s numbered 605 for semaglutide and 545 for tirzepatide as of July 2025.[13] Counts like those measure reports, not causes — the distinction the 2026 Penn analysis of 410,198 Reddit posts insists on for underreported GLP-1 side effects, whose flagged classes are reproductive and temperature-related.

Contamination is documented, not hypothetical. Forensic testing of common illicit peptide products found “arsenic and lead — in several samples at up to ten times the toxicity limit for an injectable drug — and purity that swung from about 5% to 75%.”[21] At a 2025 Las Vegas longevity festival, two attendees were hospitalized and required ventilation after unregulated injections.[9] The specific markers used to identify these products are collected in how counterfeit peptide products are identified.

A science-first checklist for consumers

Before you consider any peptide product, ask the six questions from the Star Tribune piece, plus two of our own:[1]

1. Is there a good reason to take this? What problem are you trying to solve?[1]
2. What is its legal and regulatory status? FDA-approved, on a compounding list, or in a gray zone?[1]
3. What evidence supports the specific claim? Look for human trials, not anecdotes.[1]
4. What do we know about safety by dose, route and duration? For most wellness peptides: almost nothing.[1]
5. What is in the vial, and who tested it for identity, purity and sterility? An unverifiable supply chain is a risk, not a detail.[1][21]
6. Is there an approved alternative that accomplishes the same goal? If yes, that is the evidence-based choice.[1]
7. Who is telling you about it? An influencer with a discount code has a financial incentive the science does not have.[15]
8. What happens if you’re wrong? With unapproved injectables, the downside can include contamination, immune reactions, or unknown long-term effects.[2][21]

Where the evidence actually exists

This is not a blanket attack on peptides. Insulin and semaglutide are among the most studied medicines in history.[1] Some wellness peptides have genuine preclinical promise — which is exactly why the FDA reviews them. But for most of these substances, the only thing you have is risk, because there is no established human evidence of benefit for the marketed uses.[1][10]

Athletes should note one more complication: the World Anti-Doping Agency bans BPC-157 outright under its non-approved substances class.[21]

The bottom line

The Star Tribune’s closing line is the one to remember: “The peptides did not get safer. The marketing just got better.”[1] Nothing about a peptide’s chemical structure changed in the last year. What changed is how often you see it advertised, and by whom.

PeptidesBeat exists to give you the science-first version of this story — every compound page cites the evidence we can verify and flags the evidence we cannot. Start with our peptide safety and regulatory FAQ, or go straight to our evidence reviews of BPC-157, TB-500 and KPV.

Frequently asked questions

Are peptides safe?

Some are; many marketed ones are not proven. FDA-approved peptide drugs like insulin and semaglutide have years of human safety data. The peptides sold for recovery, anti-aging and longevity — BPC-157, TB-500, KPV, MOTS-c and others — are not FDA-approved, and FDA has placed some in Category 2 as substances that may present significant safety risks.[1][2]

Are peptides FDA approved?

Some peptides are. Insulin and GLP-1 drugs like semaglutide and tirzepatide are FDA-approved after extensive testing. None of the wellness peptides commonly marketed for recovery, weight loss or longevity — BPC-157, TB-500, KPV, MOTS-c, GHK-Cu, ipamorelin — is FDA-approved.[1]

Is BPC-157 safe?

Unknown, and that is the risk. FDA’s July 2026 briefing concluded there is “insufficient clinical safety information to characterize the safety profile” of BPC-157 and found no human studies using the routes people actually use.[5] It is not FDA-approved and sits in a regulatory gray zone.[1][2]

Is TB-500 safe?

FDA states: “FDA has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment.” The safety picture is essentially an evidence gap — no approved use, no established human safety record.[2]

What does FDA Category 2 mean for peptides?

Category 2 is FDA’s designation for bulk drug substances that “may present significant safety risks” in compounding — a screening flag, not a ban and not an approval.[2] Nineteen peptides were placed there in September 2023; twelve were removed in April 2026 after nominations were withdrawn, a procedural change that resolved nothing about safety.[19][2]

How can I spot exaggerated peptide marketing claims?

Ask whether the claim matches the evidence and the regulatory record. Red flags: “research use only” fine print (legal positioning, not a safety warning), influencer discount codes (5-30% commissions), false claims of FDA approval, and ads describing uses the FDA never reviewed — BPC-157 was reviewed for ulcerative colitis, not tendon recovery or longevity.[15][1]

Sources

[1] https://www.startribune.com/peptides-not-fda-approved-glp-1s-marketing-ads-influencers-science-safety/601883791 — StarTribune (opinion): Peptides are having a moment. Here’s what the ads don’t tell you. (Aug 30, 2026) [2] https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks — FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 page) [5] https://www.fda.gov/media/193343/download — FDA PCAC briefing document, BPC-157 (July 23-24, 2026) [6] https://www.fda.gov/media/193342/download — FDA PCAC briefing document, peptide package overview (July 23-24, 2026) [7] https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html — RAPS: FDA advisory committee backs two controversial peptides (Jul 23, 2026) [9] https://www.cedars-sinai.org/stories-and-insights/healthy-living/peptides-aging-potential — Cedars-Sinai: Are Peptides an Anti-Aging Wonder Drug or a Scam? [10] https://www.npr.org/2026/07/08/nx-s1-5885073/fda-peptides-compounding-pharmacies — NPR: What’s behind the push to make peptide therapies more available (Jul 8, 2026) [13] https://www.theverge.com/column/866577/optimizer-peptides-compounding-pharmacies-glp-3-retatrutide-influencers-wellness-wild-west — The Verge: Influencers are pushing suspicious peptides (2026) [15] https://medicalxpress.com/news/2026-05-dangerous-peptides-social-media-struggling.html — MedicalXpress/The Conversation: Influencers are promoting dangerous peptides (May 2026) [16] https://www.apr.org/science-health/2026-03-24/people-are-buying-unregulated-injectable-peptides-from-chinese-factories-are-they-safe — Alabama Public Radio/NPR: People are buying unregulated injectable peptides from Chinese factories (Mar 24, 2026) [19] https://peptidelibrary.io/legal/are-peptides-legal-in-the-us — PeptideLibrary.io: Are Peptides Legal in the US? (2026 FDA Category Guide) [21] https://beachsidereader.com/article/peptides-evidence — Beachside Reader: Wellness Peptides Like BPC-157 — What’s Proven, What’s Hype

Nothing in this article is medical advice. PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.